These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 19468225

  • 1. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M, Borer JS, Tardif JC.
    Cardiology; 2009; 114(2):116-25. PubMed ID: 19468225
    [Abstract] [Full Text] [Related]

  • 2. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study.
    Köster R, Kaehler J, Meinertz T, REDUCTION Study Group.
    Am Heart J; 2009 Oct; 158(4):e51-7. PubMed ID: 19781403
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
    Borer JS, Tardif JC.
    Am J Cardiol; 2010 Jan 01; 105(1):29-35. PubMed ID: 20102886
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
    López-Bescós L, Filipova S, Martos R.
    Cardiology; 2007 Jan 01; 108(4):387-96. PubMed ID: 17890862
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct 01; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
    Koren MJ, Crager MR, Sweeney M.
    J Am Coll Cardiol; 2007 Mar 13; 49(10):1027-34. PubMed ID: 17349881
    [Abstract] [Full Text] [Related]

  • 9. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr 13; 16(88):53-6. PubMed ID: 17458043
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group.
    Indian Heart J; 2005 Apr 13; 57(6):648-54. PubMed ID: 16521631
    [Abstract] [Full Text] [Related]

  • 11. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
    Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Investigators.
    Int J Cardiol; 2013 Sep 30; 168(2):789-94. PubMed ID: 23138014
    [Abstract] [Full Text] [Related]

  • 12. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
    Ruzyllo W, Tendera M, Ford I, Fox KM.
    Drugs; 2007 Sep 30; 67(3):393-405. PubMed ID: 17335297
    [Abstract] [Full Text] [Related]

  • 13. Differential index: a simple time domain heart rate variability analysis with prognostic implications in stable angina pectoris.
    Bjorkander I, Forslund L, Kahan T, Ericson M, Held C, Rehnqvist N, Hjemdahl P.
    Cardiology; 2008 Sep 30; 111(2):126-33. PubMed ID: 18376124
    [Abstract] [Full Text] [Related]

  • 14. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Sep 30; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study.
    Ruzyllo W, Szwed H, Sadowski Z, Elikowski W, Grzelak-Szafranska H, Orszulak W, Szymczak K, Winter M.
    Curr Med Res Opin; 2004 Sep 30; 20(9):1447-54. PubMed ID: 15383193
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan 30; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS, Böhm M, Ford I, Robertson M, Komajda M, Tavazzi L, Swedberg K, SHIFT Investigators.
    Am J Cardiol; 2014 Feb 01; 113(3):497-503. PubMed ID: 24332674
    [Abstract] [Full Text] [Related]

  • 19. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Feb 01; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 20. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
    Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group.
    Circulation; 2003 Feb 18; 107(6):817-23. PubMed ID: 12591750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.